Neuropace, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
NeuroPace is a medical device company commercializing the RNS System, a brain-responsive neuromodulation system for adults with drug-resistant focal epilepsy in the United States. The company also distributes DIXI Medical products and provides data-related services under a collaboration with Rapport Therapeutics. This unaudited Form 10-Q covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023.
More than 5,000 patients had received the RNS System as of March 31, 2024. The company continues investing in commercial expansion, clinical studies, product development and potential label expansion for generalized epilepsy and patients ages 12–17.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $18.1 million | $14.5 million | +25% |
| Gross profit | $13.3 million | $10.4 million | +29% |
| Gross margin | 73.6% | 71.7% | +190 basis points |
| Research and development | $5.8 million | $5.3 million | +10% |
| Sales, general and administrative | $15.1 million | $13.4 million | +12% |
| Loss from operations | $(7.5) million | $(8.3) million | Improved by $0.8 million |
| Net loss | $(8.9) million | $(10.4) million | Improved by $1.5 million |
| Basic and diluted loss per share | $(0.32) | $(0.41) | Improved |
| Net cash used in operations | $(7.5) million | $(9.7) million | Improved by $2.2 million |
Revenue growth was primarily driven by higher initial-implant unit volume and increased DIXI Medical sales, partly offset by lower replacement-procedure volume. Replacement-procedure revenue represented approximately 4% of total revenue versus 8% in the prior-year quarter. Substantially all revenue was generated in the United States.
Gross margin improved primarily because increased RNS production volume reduced fixed manufacturing costs per unit and service revenue carried higher margins. The benefit was partly offset by lower margins on DIXI Medical distribution. Operating expenses increased faster than revenue in absolute dollars, and the company remained significantly loss-making.
At March 31, 2024, the company had cash and cash equivalents of $13.0 million, short-term investments of $45.9 million and total cash, cash equivalents and short-term investments of $58.9 million, compared with $66.5 million at December 31, 2023. Current liabilities were $13.1 million, and the company reported an accumulated deficit of $512.7 million.
Operating cash usage was $7.5 million. Investing cash inflow of $2.4 million primarily reflected $2.5 million of short-term investment sales, while financing activities provided $0.1 million, mainly from employee stock-plan exercises net of taxes withheld. Cash and cash equivalents, including restricted cash, declined by $5.1 million during the quarter to $13.1 million.
Debt, capital structure and liquidity risks
Term-loan debt, net of debt discount and issuance costs, was $58.0 million at March 31, 2024, compared with $57.0 million at December 31, 2023. The loan carries a 13.5% stated interest rate and had an effective interest rate of approximately 16.9%. The company used the paid-in-kind interest option through March 2024, adding approximately $0.7 million of principal during the quarter. The loan is secured by substantially all company assets, including intellectual property, and includes a 10% repayment fee on principal repaid or prepaid.
The 2024 minimum annual net revenue covenant is $70.0 million, and the minimum cash and cash equivalents covenant is $5.0 million. The company stated that it was in compliance with all covenants at March 31, 2024. In May 2024, after the reporting date, the loan was amended to extend final maturity from September 30, 2025 to September 30, 2026 and eliminate the PIK interest option after June 30, 2024.
Management believes available cash, cash equivalents and short-term investments will fund planned operations for at least 12 months from issuance of the interim financial statements. However, the company expects continued operating losses and negative operating cash flow and may need additional equity or debt financing. It had $41.9 million remaining under its ATM equity program at March 31, 2024; no ATM shares were sold during the quarter.
Material changes versus the prior comparable period
- Revenue increased 25%, driven by initial RNS implant volume and DIXI Medical sales.
- Gross margin increased from 71.7% to 73.6%.
- Research and development expense rose 10%, primarily from higher personnel-related costs, partly offset by increased NIH grant funding.
- SG&A expense rose 12%, primarily from higher sales and field-support personnel costs, severance and marketing-related spending.
- Net loss improved 14%, although the company remained unprofitable.
- Operating cash burn improved by $2.2 million, but cash and short-term investments declined by $7.6 million from year-end.
- Interest expense increased 15% because of the higher loan balance resulting from PIK interest and the increased interest rate.
- Stock-based compensation increased to $2.5 million from $2.1 million.
Guidance, outlook, management commentary and risks
The filing does not provide a clear numerical revenue or earnings guidance range. Management expects revenue growth and continued investment in sales and marketing, clinical studies, regulatory activities, product enhancements and potential indication expansion. It also expects to incur net losses and negative cash flows for the next several years.
Key operating priorities include expanding RNS adoption beyond Level 4 comprehensive epilepsy centers, increasing referrals, improving sales-force productivity, leveraging the DIXI Medical relationship and developing evidence for expanded indications. Management believes existing manufacturing capacity can support current and near-term needs.
- Debt and covenant risk: Failure to achieve the $70.0 million 2024 revenue covenant or maintain minimum cash could result in a loan default and acceleration of debt, potentially requiring additional capital.
- Capital needs: Continued losses, cash burn and substantial secured debt may require future equity or debt financing, which could be dilutive or unavailable on acceptable terms.
- Commercial adoption: Growth depends on clinician, hospital and patient adoption, referral volumes, reimbursement and the productivity and retention of the direct sales force.
- Competition: NeuroPace competes with larger, better-capitalized companies and alternative treatments, including VNS, DBS, resective or ablative surgery and drug therapies.
- Regulatory and clinical risk: Product modifications, post-approval studies and proposed label expansions require regulatory compliance and may be delayed, rejected or limited.
- Manufacturing and supply chain: The company manufactures at one Mountain View facility and relies on several single-source suppliers for critical components, including batteries and printed circuit assemblies.
- Reimbursement and pricing: Changes in coverage, reimbursement rates or healthcare cost-containment policies could reduce demand or margins.
- Data privacy and cybersecurity: The RNS System and clinical activities involve sensitive patient and brain-activity data, creating regulatory, operational and reputational exposure.
- Unusual items: Q1 SG&A included severance costs; the company also recognized approximately $0.7 million of non-cash PIK interest and $2.5 million of stock-based compensation.
The company reported no material pending legal proceedings, no required contingency accruals and effective disclosure controls as of March 31, 2024.
Important facts for investors to verify
- Progress toward the $70.0 million 2024 annual revenue covenant and compliance with the $5.0 million minimum cash covenant.
- Cash burn, available liquidity and the timing or terms of any future financing.
- Impact of the May 2024 debt amendment, including the end of PIK interest and the extended maturity date.
- Whether initial-implant growth offsets declining replacement-procedure revenue and the effect of product mix on gross margin.
- Adoption of the RNS System outside Level 4 comprehensive epilepsy centers and productivity of the expanded commercial organization.
- Reimbursement stability, clinical-study results and regulatory progress for proposed indication expansions.
- Reliability of single-source suppliers and the company’s ability to maintain production at its single manufacturing facility.
- Future operating leverage, stock-based compensation, severance and other costs required to pursue growth.